|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.300 SEK | 0.00% |
|
0.00% | +40.69% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 45.63M | - | ||||
| 55.35B | |||||
| 51.92B | |||||
| 22.76B | - | ||||
| 22.64B | - | ||||
| 17.36B |
- Stock Market
- Stocks
- IVACC Stock
- Charts Intervacc AB
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
